ABVC BioPharma Announces Completion Of Subject Recruitment For Interim Analysis On ADHD Phase IIb Clinical Study
Portfolio Pulse from Benzinga Newsdesk
ABVC BioPharma has completed subject recruitment for an interim analysis on its ADHD Phase IIb clinical study. The study involves approximately 100 patients in the US and Taiwan. The Phase IIb study continues the Phase IIa study of ABV-1505, which achieved its primary endpoints and was accepted by the FDA in October 2020. The global ADHD treatment market is expected to reach $32.14 billion by 2030.
October 17, 2023 | 12:41 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ABVC BioPharma's completion of subject recruitment for its ADHD Phase IIb clinical study could potentially boost its position in the ADHD treatment market, which is expected to reach $32.14 billion by 2030.
The completion of subject recruitment for ABVC BioPharma's ADHD Phase IIb clinical study signifies progress in the company's clinical trials. Given the projected growth of the ADHD treatment market, this could potentially enhance ABVC BioPharma's market position and positively impact its stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100